Format
Sort by
Items per page

Send to

Choose Destination

Best matches for disclosure employment:

Search results

Items: 1 to 20 of 1941

1.

[Epidemiology and sociodemographic characterization of the fibromyalgia in Comunidad Valenciana].

Cabo-Meseguer A, Cerdá-Olmedo G, Trillo-Mata JL.

Rev Esp Salud Publica. 2019 Dec 13;93. pii: e201912099. Spanish.

2.

Substantial remission of prostate adenocarcinoma with dendritic cell therapy APCEDEN® in combination with chemotherapy.

Kumar C, Bagga J, Chiliveru S, Kohli S, Bharadwaj A, Jain M, Inamdar S, Sharan B.

Future Sci OA. 2019 Oct 29;5(10):FSO435. doi: 10.2144/fsoa-2019-0086.

3.

On the future of therapeutic vaccination in chronic hepatitis B.

Aguilar Rubido JC.

Future Sci OA. 2019 Oct 30;5(10):FSO426. doi: 10.2144/fsoa-2019-0104. No abstract available.

4.

Battle of Thermopylae: 300 Spartans (natural killer cells plus obinutuzumab) versus the immortal warriors (chronic lymphocytic leukemia cells) of Xerxes' army.

García-Muñoz R, Nájera MJ, Feliu J, Antón-Remírez J, Ramalle-Gómara E, Marín-Gorricho R, Peralta R, Gutiérrez-Gamarra E, Nuñez-Rodriguez J, Zafra-Morales R, Aguinaga L, Nebot-Villacampa MJ, Hernandez-Pérez PM, Farfán-Quiroga G, Panizo C, Domínguez-Garrido E.

Future Sci OA. 2019 Nov 26;5(10):FSO425. doi: 10.2144/fsoa-2019-0064.

5.

Plasma PARK7 and NDKA in acute stroke: methodological issues regarding diagnostic value.

Sabour S.

Future Sci OA. 2019 Oct 30;5(10):FSO424. doi: 10.2144/fsoa-2019-0078. No abstract available.

6.

Practices of patients consuming antibiotics and knowledge about antibiotic resistance in Hail region - Saudi Arabia.

Benmerzouga I, Al-Zammay SA, Al-Shammari MM, Alsaif SA, Alhaidan TM, Aljofan M.

Future Sci OA. 2019 Sep 27;5(10):FSO420. doi: 10.2144/fsoa-2019-0054.

7.

Representation of concussion subtypes in common postconcussion symptom-rating scales.

Lumba-Brown A, Ghajar J, Cornwell J, Bloom OJ, Chesnutt J, Clugston JR, Kolluri R, Leddy JJ, Teramoto M, Gioia G.

Concussion. 2019 Nov 1;4(3):CNC65. doi: 10.2217/cnc-2019-0005. Review.

8.

Supporting choices about HIV disclosure in the workplace: A Cross-Canada survey of strategies.

Restall G, Simms A, Etcheverry E, Roger K, James D, Roddy P, Porch W, Potts J, Skitch D, Yates T.

Work. 2019 Dec 3. doi: 10.3233/WOR-193035. [Epub ahead of print]

PMID:
31815713
9.

An update on adjuvant systemic therapies in melanoma.

Samuel E, Moore M, Voskoboynik M, Shackleton M, Haydon A.

Melanoma Manag. 2019 Nov 13;6(3):MMT28. doi: 10.2217/mmt-2019-0009. Review.

10.

Systemic therapies for unresectable locoregional melanoma: a significant area of need.

Nan Tie E, Lai-Kwon JE, Gyorki DE.

Melanoma Manag. 2019 Sep 2;6(3):MMT25. doi: 10.2217/mmt-2019-0010. Review.

11.

An evidence-based approach to positive sentinel node disease: should we ever do a completion node dissection?

Downs JS, Gyorki DE.

Melanoma Manag. 2019 Oct 18;6(3):MMT24. doi: 10.2217/mmt-2019-0011. Review.

12.

Topical and intralesional therapies for in-transitmelanoma.

Henderson MA.

Melanoma Manag. 2019 Sep 2;6(3):MMT23. doi: 10.2217/mmt-2019-0008. Review.

13.

Locoregional melanoma: identifying optimal care in a rapidly changing landscape.

Gyorki DE, Zager JS.

Melanoma Manag. 2019 Nov 28;6(3):MMT22. doi: 10.2217/mmt-2019-0014. No abstract available.

14.

Identifying successful biomarkers for patients with non-small-cell lung cancer.

Friedlaender A, Bauml J, Banna GL, Addeo A.

Lung Cancer Manag. 2019 Nov 14;8(3):LMT17. doi: 10.2217/lmt-2019-0009. No abstract available.

15.

Biopsy and rebiopsy for non-small-cell lung cancer: current and future methods.

Zarogoulidis P, Kosmidis C, Fyntanidou V, Aidoni Z, Tsakiridis K, Koulouris C, Michalopoulos N, Barmpas A, Huang H, Bai C, Hohenforst-Schmidt W, Sapalidis K.

Lung Cancer Manag. 2019 Oct 17;8(3):LMT16. doi: 10.2217/lmt-2019-0006. No abstract available.

16.

Afatinib in locally advanced/metastatic NSCLC harboring common EGFR mutations, after chemotherapy: a Phase IV study.

Thongprasert S, Geater SL, Clement D, Abdelaziz A, Reyes-Igama J, Jovanovic D, Alexandru A, Schenker M, Sriuranpong V, Serwatowski P, Suresh S, Cseh A, Gaafar R.

Lung Cancer Manag. 2019 Sep 2;8(3):LMT15. doi: 10.2217/lmt-2019-0004.

17.

Stereotactic body radiation therapy versus fractionated radiation therapy for early-stage bronchopulmonary carcinoid.

Wegner RE, Abel S, Horne ZD, Hasan S, Colonias A, Verma V.

Lung Cancer Manag. 2019 Aug 21;8(3):LMT14. doi: 10.2217/lmt-2019-0003.

18.

Living with multiple sclerosis in South Africa: how is multiple sclerosis experienced in the workplace?

Kruger H, Coetzee BJ.

Disabil Rehabil. 2019 Nov 21:1-10. doi: 10.1080/09638288.2019.1691274. [Epub ahead of print]

PMID:
31749414
19.

Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study.

Tam CS, Siddiqi T, Allan JN, Kipps TJ, Flinn IW, Kuss BJ, Opat S, Barr PM, Tedeschi A, Jacobs R, Badoux XC, Ghia P, Sukbuntherng J, Salem AH, Russell K, Eckert K, Zhou C, Ninomoto J, James DF, Wierda WG.

Blood. 2019 Nov 13;134(Supplement_1):35. doi: 10.1182/blood-2019-121424.

PMID:
31724017
20.

Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines.

Schuster SJ, Bartlett NL, Assouline S, Yoon SS, Bosch F, Sehn LH, Cheah CY, Shadman M, Gregory GP, Ku M, Wei MC, Yin S, Kwan A, Yousefi K, Hernandez G, Li CC, O'Hear C, Budde LE.

Blood. 2019 Nov 13;134(Supplement_1):6. doi: 10.1182/blood-2019-123742.

PMID:
31723992

Supplemental Content

Loading ...
Support Center